News release via Canada NewsWire, Toronto 416-863-9350
Attention Business Editors

Patheon Inc. Corrects Reported Voting Results of its 2009 Annual Meeting of Shareholders

Toronto, (May 7, 2009) /CNW/ Patheon Inc. (TSX: PTI), a global provider of drug development and manufacturing services to the international pharmaceutical industry, announced that it has filed voting results in respect of its 2009 annual meeting of its shareholders.  The voting results originally filed on SEDAR on May 1, 2009 overstated the number of votes cast in favour of Messrs. Bussandri, Currie, Green, Watchorn, Voorheis and Graydon by 4,514,200.  The corrected voting results did not affect the determination of which individuals were elected to the board of directors of the Company at the meeting. 

ABOUT PATHEON

Patheon Inc. (TSX: PTI; www.patheon.com) is a leading global provider of contract development and manufacturing services to the global pharmaceutical industry.  Patheon prides itself in providing the highest quality products and services to more than 300 of the world’s leading pharmaceutical and biotechnology companies. Patheon’s services range from preclinical development through commercial manufacturing of a full array of dosage forms including parenteral, solid, semi-solid and liquid forms.  Patheon uses many innovative technologies including single-use disposables, Liquid-Filled Hard Capsules and a variety of modified release technologies. 

Patheon’s comprehensive range of fully integrated Pharmaceutical Development Services includes pre-formulation, formulation, analytical development, clinical manufacturing, scale-up and commercialization.  Patheon can take customers direct to clinic with global clinical packaging and distribution services and Patheon’s Quick to Clinic™ programs can accelerate early phase development project to clinical trials while minimizing the consumption of valuable API.  Patheon’s integrated network strives to ensure that customer products can be launched with confidence globally.